Endeavor Private Wealth Inc. Buys Shares of 2,835 Astrazeneca Plc $AZN

Endeavor Private Wealth Inc. bought a new stake in Astrazeneca Plc (NYSE:AZN) in the 4th quarter, Holdings Channel.com reports. The fund bought 2,835 shares of the company’s stock, valued at approximately $498,000.

Other large investors have also recently bought and sold shares of the company. Cibc World Market Inc. boosted its holdings in shares of Astrazeneca by 21.5% in the third quarter. Cibc World Market Inc. now owns 64,421 shares of the company’s stock valued at $4,942,000 after buying an additional 11,398 shares during the period. TD Asset Management Inc boosted its holdings in Astrazeneca by 20.0% during the third quarter. TD Asset Management Inc now owns 1,089,612 shares of the company’s stock worth $83,595,000 after purchasing an additional 181,273 shares during the last quarter. AMG National Trust Bank boosted its holdings in Astrazeneca by 20.4% during the third quarter. AMG National Trust Bank now owns 42,983 shares of the company’s stock worth $3,298,000 after purchasing an additional 7,289 shares during the last quarter. Assetmark Inc. boosted its holdings in Astrazeneca by 6.5% during the third quarter. Assetmark Inc. now owns 310,383 shares of the company’s stock worth $23,813,000 after purchasing an additional 19,020 shares during the last quarter. Finally, US Bancorp DE boosted its holdings in Astrazeneca by 6.6% during the third quarter. US Bancorp DE now owns 242,181 shares of the company’s stock worth $18,581,000 after purchasing an additional 15,065 shares during the last quarter. Institutional investors own 20.35% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research analysts recently commented on AZN shares. Jefferies Financial Group restated a “buy” rating on shares of Astrazeneca in a report on Wednesday, May 13th. Wall Street Zen upgraded shares of Astrazeneca from a “hold” rating to a “buy” rating in a report on Saturday, May 2nd. Weiss Ratings started coverage on shares of Astrazeneca in a report on Wednesday, March 11th. They set a “buy (b)” rating for the company. Deutsche Bank Aktiengesellschaft restated a “sell” rating on shares of Astrazeneca in a report on Thursday, May 21st. Finally, DZ Bank upgraded shares of Astrazeneca from a “neutral” rating to a “buy” rating in a report on Wednesday, April 29th. Twelve analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $205.33.

Astrazeneca Stock Performance

Shares of AZN stock opened at $186.06 on Monday. The stock has a market cap of $288.57 billion, a P/E ratio of 27.94, a P/E/G ratio of 1.59 and a beta of 0.25. The company has a debt-to-equity ratio of 0.52, a current ratio of 0.91 and a quick ratio of 0.71. The company has a fifty day moving average price of $190.84 and a two-hundred day moving average price of $185.34. Astrazeneca Plc has a one year low of $137.23 and a one year high of $212.71.

Astrazeneca (NYSE:AZN) last announced its quarterly earnings results on Wednesday, April 29th. The company reported $2.58 EPS for the quarter, beating analysts’ consensus estimates of $2.52 by $0.06. The firm had revenue of $15.29 billion during the quarter, compared to analysts’ expectations of $14.93 billion. Astrazeneca had a net margin of 17.19% and a return on equity of 30.86%. As a group, equities analysts predict that Astrazeneca Plc will post 9.52 EPS for the current year.

Astrazeneca Profile

AstraZeneca plc is a global biopharmaceutical company headquartered in Cambridge, England. Formed through the 1999 merger of Sweden’s Astra AB and the UK’s Zeneca Group, the company researches, develops, manufactures and commercializes prescription medicines across a range of therapeutic areas. AstraZeneca positions itself as R&D-driven, investing in discovery science, clinical development and regulatory processes to bring new therapies to market.

The company’s commercial portfolio and late-stage pipeline emphasize oncology, cardiovascular, renal and metabolic (CVRM) diseases, and respiratory and immunology.